Dr. Rupert M. Bauersachs, of Klinikum Darmstadt and University of Mainz, Germany, discusses the results of the latest update from the VOYAGER PAD trial with Dr. Ron Waksman. The study, presented as a late-breaking trial at ACC.21 Virtual, showed that rivaroxaban significantly reduced the otherwise high total event burden for peripheral artery disease patients undergoing lower-extremity revascularization by 14%.